BETHESDA, Md. - An FDA advisory panel unanimously agreed that Cephalon Inc.'s wake-promoting agent, Provigil, is effective in treating excessive sleepiness associated with sleep apnea. And in a 6-2 vote, the panel said Cephalon's data supported the claim that Provigil is effective in the treatment of excessive sleepiness in patients with shift-worker sleep disorder. (BioWorld Today)
BETHESDA, Md. - An FDA advisory panel unanimously agreed that Cephalon Inc.'s wake-promoting agent, Provigil, is effective in treating excessive sleepiness associated with sleep apnea. And in a 6-2 vote, the panel said Cephalon's data supported the claim that Provigil is effective in the treatment of excessive sleepiness in patients with shift-worker sleep disorder. (BioWorld Today)
Although AEterna Laboratories Inc. missed the primary endpoint in a Phase III trial of Neovastat in renal-cell carcinoma, the company Wednesday said a subgroup of earlier-stage cancer patients demonstrated a significant survival benefit. (BioWorld Today)
Although AEterna Laboratories Inc. missed the primary endpoint in a Phase III trial of Neovastat in renal-cell carcinoma, the company Wednesday said a subgroup of earlier-stage cancer patients demonstrated a significant survival benefit. (BioWorld Today)
A team of executives from Adolor Corp. and partner GlaxoSmithKline plc Tuesday said statistically significant data from a second Phase III study of Entereg in the management of postoperative ileus nudges the companies one step closer to submitting a regulatory package next year. (BioWorld Today)
A team of executives from Adolor Corp. and partner GlaxoSmithKline plc Tuesday said statistically significant data from a second Phase III study of Entereg in the management of postoperative ileus nudges the companies one step closer to submitting a regulatory package next year. (BioWorld Today)
